The developmental potential of parthenogenetic and somatic cell nuclear-transferred rat oocytes in vitro.
We examined the optimal conditions for somatic cell nuclear transfer (SCNT) in rat oocytes. First, we compared the effects of two types of inhibitors of spontaneous activation, MG132 and demecolcine, on the developmental potential of parthenogenetic oocytes. The potential of activated oocytes to develop into blastocysts significantly decreased 2 h after oocyte recovery (77% vs. 7%). The developmental potential of oocytes preserved in MG132-supplemented medium for 1 to 4 h was high (62% to 77%), but the potential of those preserved in demecolcine-supplemented medium for 3 and 4 h was low (77% vs. 41% and 37%, respectively). Second, the effect of the duration of parthenogenetic activation on the developmental potential was examined. When oocytes preserved in MG132 for 4 h were treated with 10 mM strontium for 5 or 6 h, the potential of activated oocytes to develop into blastocysts was high (78% and 70%, respectively). Using the optimal conditions for parthenogenetic activation, we examined the potential of rat enucleated oocytes receiving cumulus cells to develop into blastocysts. In contrast to parthenogenotes, the potential of SCNT rat oocytes to develop into blastocysts was low (2%) even if then oocytes were treated with the histone deacetylation inhibitor trichostatin A. The reason for the low developmental potential of rat SCNT oocytes is discussed.
Mizumoto
Shigetoshi
S
Laboratory of Animal Reproduction, College of Agriculture, Kinki University, Nara, 631-8505, Japan.
Kato
Yoko
Y
Tsunoda
Yukio
Y
D000818:Animals; D001757:Blastomeres / Q000187:drug effects / Q000502:physiology; D019976:Cloning, Organism / Q000379:methods*; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D003703:Demecolcine / Q000494:pharmacology; D047108:Embryonic Development / Q000502:physiology; D005260:Female; D006877:Hydroxamic Acids / Q000494:pharmacology; D007976:Leupeptins / Q000494:pharmacology; D053652:Nuclear Transfer Techniques; D009865:Oocytes / Q000187:drug effects / Q000254:growth & development*; D010312:Parthenogenesis / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D050257:Tubulin Modulators / Q000494:pharmacology
D015853:Cysteine Proteinase Inhibitors; D006877:Hydroxamic Acids; D007976:Leupeptins; D050257:Tubulin Modulators; C012589:trichostatin A; C072553:benzyloxycarbonylleucyl-leucyl-leucine aldehyde; D003703:Demecolcine